Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 1 11Phase 1/2 5Phase NA 1Phase 3 1

Status

Recruiting 12Active not recruiting 10Completed 6Terminated 5Unknown 3Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 2Genitourinary 2Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 2Ovarian Neoplasms 2Pancreatic Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Breast Neoplasms 1Advanced Solid Tumor, Adult 1Adenocarcinoma 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × olaparib × Clear all
NCT04972110 2025-10-30

ATTACC

Repare Therapeutics

Phase 1/2 Terminated
156 enrolled 19 charts
Other solid neoplasm

Advanced Solid Tumor, Adult

NCT05405309 2025-06-03

CORONADO CLL

University of Utah

Phase 1/2 Terminated
5 enrolled 13 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04556617 2025-04-08

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Opna Bio LLC

Phase 1/2 Terminated
19 enrolled 11 charts
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT04826198 2024-12-05

REVOCAN

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Terminated
13 enrolled
Gynecologic

Ovarian Neoplasms

NCT06065059 2024-08-13

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Tango Therapeutics, Inc.

Phase 1/2 Terminated
7 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡